RS62924B1 - Nova upotreba n,n-bis-2-merkaptoetil izoftalamida - Google Patents

Nova upotreba n,n-bis-2-merkaptoetil izoftalamida

Info

Publication number
RS62924B1
RS62924B1 RS20220147A RSP20220147A RS62924B1 RS 62924 B1 RS62924 B1 RS 62924B1 RS 20220147 A RS20220147 A RS 20220147A RS P20220147 A RSP20220147 A RS P20220147A RS 62924 B1 RS62924 B1 RS 62924B1
Authority
RS
Serbia
Prior art keywords
paracetamol
nbmi
toxicity
pharmaceutically acceptable
administration
Prior art date
Application number
RS20220147A
Other languages
English (en)
Serbian (sr)
Inventor
Boyd Eugene Haley
Ragnar Axel Theodor Klingberg
Original Assignee
Emeramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emeramed Ltd filed Critical Emeramed Ltd
Publication of RS62924B1 publication Critical patent/RS62924B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RS20220147A 2016-08-05 2017-08-04 Nova upotreba n,n-bis-2-merkaptoetil izoftalamida RS62924B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201613535 2016-08-05
PCT/GB2017/052306 WO2018025049A1 (en) 2016-08-05 2017-08-04 New use of n,n-bis-2-mercaptoethyl isophthalamide
EP17793720.8A EP3493849B1 (en) 2016-08-05 2017-08-04 New use of n,n-bis-2-mercaptoethyl isophthalamide

Publications (1)

Publication Number Publication Date
RS62924B1 true RS62924B1 (sr) 2022-03-31

Family

ID=60202272

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220147A RS62924B1 (sr) 2016-08-05 2017-08-04 Nova upotreba n,n-bis-2-merkaptoetil izoftalamida

Country Status (31)

Country Link
US (2) US20190240173A1 (enExample)
EP (2) EP4029497A1 (enExample)
JP (1) JP6926192B2 (enExample)
KR (1) KR102538388B1 (enExample)
CN (1) CN109562179A (enExample)
AU (1) AU2017305661B2 (enExample)
BR (1) BR112019002130A2 (enExample)
CL (1) CL2019000229A1 (enExample)
CY (1) CY1125039T1 (enExample)
DK (1) DK3493849T3 (enExample)
EA (1) EA201990443A1 (enExample)
ES (1) ES2907838T3 (enExample)
HR (1) HRP20220252T1 (enExample)
HU (1) HUE057782T2 (enExample)
IL (1) IL264538B2 (enExample)
LT (1) LT3493849T (enExample)
MA (1) MA45855B1 (enExample)
MD (1) MD3493849T2 (enExample)
MX (1) MX387853B (enExample)
MY (1) MY199733A (enExample)
NZ (1) NZ750271A (enExample)
PH (1) PH12019500237A1 (enExample)
PL (1) PL3493849T3 (enExample)
PT (1) PT3493849T (enExample)
RS (1) RS62924B1 (enExample)
SG (1) SG11201900565RA (enExample)
SI (1) SI3493849T1 (enExample)
SM (1) SMT202200109T1 (enExample)
UA (1) UA125394C2 (enExample)
WO (1) WO2018025049A1 (enExample)
ZA (1) ZA201900594B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
US8950583B2 (en) * 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
US20120122787A1 (en) * 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
AU2010297933A1 (en) 2009-09-28 2012-04-19 University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use
US8426368B2 (en) 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands

Also Published As

Publication number Publication date
MA45855B1 (fr) 2022-02-28
MA45855A (fr) 2021-03-17
EP4029497A1 (en) 2022-07-20
AU2017305661B2 (en) 2023-05-18
EA201990443A1 (ru) 2019-07-31
CY1125039T1 (el) 2023-03-24
EP3493849A1 (en) 2019-06-12
JP2019524782A (ja) 2019-09-05
PT3493849T (pt) 2022-02-23
ZA201900594B (en) 2019-08-28
KR20190035724A (ko) 2019-04-03
CA3032858A1 (en) 2018-02-08
LT3493849T (lt) 2022-03-10
MX2019000978A (es) 2019-06-10
KR102538388B1 (ko) 2023-05-30
IL264538B (en) 2022-10-01
US20250325503A1 (en) 2025-10-23
PL3493849T3 (pl) 2022-03-28
US20190240173A1 (en) 2019-08-08
MD3493849T2 (ro) 2022-04-30
CL2019000229A1 (es) 2019-04-26
MX387853B (es) 2025-03-19
MY199733A (en) 2023-11-21
WO2018025049A1 (en) 2018-02-08
SMT202200109T1 (it) 2022-05-12
ES2907838T3 (es) 2022-04-26
HUE057782T2 (hu) 2022-06-28
AU2017305661A1 (en) 2019-02-14
BR112019002130A2 (pt) 2019-05-14
HRP20220252T1 (hr) 2022-04-29
JP6926192B2 (ja) 2021-08-25
IL264538B2 (en) 2023-02-01
EP3493849B1 (en) 2021-12-01
NZ750271A (en) 2025-07-25
UA125394C2 (uk) 2022-03-02
SG11201900565RA (en) 2019-02-27
SI3493849T1 (sl) 2022-04-29
PH12019500237A1 (en) 2019-10-28
CN109562179A (zh) 2019-04-02
IL264538A (enExample) 2019-03-31
DK3493849T3 (en) 2022-03-07

Similar Documents

Publication Publication Date Title
JP6353577B2 (ja) 組み合わせ組成物
JP2010180244A (ja) 肝癌発生・進展抑制剤
JP2015519404A5 (enExample)
JPWO2004019928A1 (ja) 肝疾患治療剤
BR112020001074A2 (pt) composição
US20250325503A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
RU2586742C2 (ru) Композиция для лечения метаболических расстройств
US7825156B2 (en) Method of treating bipolar depression with a benzamide derivative
ITMI20130349A1 (it) Composizione per uso nel trattamento della sindrome dell ovaio policistico
AU2011274652B2 (en) A combination composition comprising ibuprofen and paracetamol
CA3032858C (en) Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity
HK40005150B (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
JPWO2005089743A1 (ja) 腎性貧血治療剤
WO2007018278A1 (ja) 肝癌発生・進展抑制剤
US20250152537A1 (en) Compositions and methods for the treatment of human immunodeficiency virus
US20250228808A1 (en) Compositions and methods for the treatment of coronavirus diseases
JP5908761B2 (ja) 食後過血糖の予防又は改善剤
BR112019005039B1 (pt) Método de redução dos efeitos colaterais associados à tireoide
WO2014150318A1 (en) Therapeutic agent for enhancing mitochondrial function
JP2009084253A (ja) 頭痛の予防および/または治療剤
JP2010184936A (ja) 放射線被爆患者の処置方法